Pharmacogenomic Effect/ADR for Rituximab (DBSNPE000160)

DocumentationBrowse all
Identifier
DBSNPE000160
Drug
Rituximab (DB00073)
Interacting Gene/Enzyme
Low affinity immunoglobulin gamma Fc region receptor III-A
Gene Name
FCGR3A
UniProt ID
P08637
Defining Change(s)
T > Grs396991
Allele Name
FCGR3A
Genotype(s)
(G;G) / (G;T)
Type(s)
Effect Directly Studied
Groups
Not Available
Description
Patients with this genotype have increased frequency of anti-tumor response when using rituximab to treat diffuse large B-cell lymphoma, follicular lymphoma, or [follicular non-Hodgkin lymphoma].
References
  1. Kim DH, Jung HD, Kim JG, Lee JJ, Yang DH, Park YH, Do YR, Shin HJ, Kim MK, Hyun MS, Sohn SK: FCGR3A gene polymorphisms may correlate with response to frontline R-CHOP therapy for diffuse large B-cell lymphoma. Blood. 2006 Oct 15;108(8):2720-5. Epub 2006 Apr 11. [Article]